Related Experiment Video

Updated: Aug 22, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Novel oncogenic protein kinase inhibitors for cancer therapy

Tomi K Sawyer1

  • 1ARIAD Pharmaceuticals, Inc., 26 Landsdowne St., Cambridge, MA 01772, USA. tomi.sawyer@ariad.com

Current Medicinal Chemistry. Anti-Cancer Agents
|September 24, 2004
PubMed

Insights

Small-molecule cancer drug discovery is advancing novel oncogenic protein kinase inhibitors. Structure- and mechanism-based design, target selectivity, and drug resistance mutations are key areas of progress.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Small-molecule drug discovery is crucial for cancer therapy.
  • Novel oncogenic protein kinase inhibitors show significant impact in research and clinical settings.

Purpose of the Study:

  • To highlight progress in structure- and mechanism-based drug design for kinase inhibitors.
  • To discuss evolving concepts in oncogenic kinase inhibitor discovery, focusing on target selectivity and drug resistance.

Main Methods:

  • Review of structure- and mechanism-based drug design principles.
  • Analysis of evolving concepts in kinase inhibitor development.
  • Examination of oncogenic kinase mutants and their role in drug response.

Main Results:

  • Structure- and mechanism-based design approaches are advancing kinase inhibitor development.
  • Target selectivity and understanding drug resistance mutations are critical for effective therapies.
  • Identification of specific kinase mutants influences susceptibility or resistance to inhibitors.

Conclusions:

  • Continued progress in small-molecule kinase inhibitor discovery offers promising avenues for cancer treatment.
  • Integrating structural, mechanistic, and resistance data is essential for future drug design.
  • Personalized approaches considering kinase mutations will improve therapeutic outcomes.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...